Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. announced the completion of the sale of its sevasemten compound and muscular dystrophy program to Servier Pharmaceuticals LLC and Les Laboratoires Servier. The transaction involved $1.55 billion in upfront cash and up to $1.1 billion in additional milestone payments, for a total potential consideration of $2.65 billion. This divestment strengthens Edgewise's balance sheet and allows the company to strategically focus on advancing its cardiovascular pipeline, with the upfront proceeds expected to fully fund EDG-7500 development through potential approval.

Edgewise Therapeutics announced an Asset Purchase Agreement to sell its sevasemten compound and neuromuscular program to Servier for up to $2.65 billion. The deal includes $1.55 billion in upfront cash and up to $1.1 billion in potential regulatory and commercial milestone payments. This transaction strengthens Edgewise's balance sheet, providing financial flexibility to advance its cardiovascular pipeline, and allows the company to become a cardiovascular-focused entity. The transaction is expected to close in Q3 2026.

Edgewise Therapeutics reported a net loss of $49.0 million, or $0.46 per share, for the first quarter of 2026, an increase from $40.8 million, or $0.43 per share, in the same period of 2025. Research and development expenses rose to $42.7 million, primarily due to increased clinical development activity for EDG-7500 and EDG-15400. The company also announced positive long-term data for sevasemten in Becker muscular dystrophy, demonstrating sustained functional stabilization, and anticipates key clinical data readouts for EDG-7500 in Q2 2026 and pivotal GRAND CANYON results for sevasemten in Q4 2026.

Edgewise Therapeutics reported a net loss of $(49.0) million for the first quarter of 2026, an increase from $(40.8) million in the prior year, primarily due to higher operating expenses. Research and development expenses rose by 16% to $42.7 million as the company continued to advance its late-stage clinical programs for severe muscle diseases. As of March 31, 2026, the company held $499.6 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next 12 months.